pcn poster

Posters

Challenges and Considerations in Design of a Placebo-Controlled, Double-Blind, Randomized-Withdrawal Study Evaluating the Efficacy and Safety of JZP-258 for the Treatment of Idiopathic Hypersomnia

No treatment is approved for idiopathic hypersomnia (IH). A retrospective chart review (Leu-Semenescu, et al. Sleep Med. 2016;17:38-44) demonstrated effectiveness of sodium oxybate (SXB) ...

Patricia Chandler , MD;

Dandan Chen , MD, PhD;

Judith Profant , PhD, MS;

Amanda Sterkel , PhD;

Yves Dauvilliers , MD, PhD;

10/08/2020

A randomized, placebo-controlled trial to evaluate the efficacy and safety of AR19 (amphetamine sulfate) in adults with attention-deficit/hyperactivity disorder

Background: AR19 is a pellets-in-capsule, immediate-release amphetamine sulfate investigational formulation with physical and chemical barriers designed to resist manipulation to deter sn...

Steven Caras , MD, PhD;

Anthony Rostain , MD;

Stephen V. Faraone , PhD;

10/08/2020

All-cause Healthcare Resource Utilization and Costs Among Patients With Episodic or Chronic Migraine and Comorbid Depression and/or Anxiety

Objective: This real-world retrospective cohort study evaluated healthcare resource utilization (HCRU) and costs for adult patients with episodic migraine (EM) or chronic migraine (CM) an...

Guihua Zhang ;

Dawn Buse ;

Joshua P. Cohen , PhD;

Patricia Pozo-Rosich ;

Krishna Tangirala ;

Stephen Thompson ;

Lynda Krasenbaum ;

10/08/2020

Antidepressant and Psychotherapy Treatment among Patients With Major Depressive Disorder and an Elevated PHQ-9 Score

Background The PHQ-9 measures depression symptom severity and is recommended for use in clinical practice among patients with major depressive disorder (MDD). Objective To describe treat...

Charles Ruetsch , PhD;

Joshua Liberman , PhD;

Felicia Forma , BSc;

Pinyao Rui , PhD;

Alberto Batista , PharmD;

10/08/2020

An Assessment of the Impact of Prior Antipsychotic Treatment on the Duration of Treatment with RBP-7000 during a Long-Term Safety Study

Introduction: RBP-7000 (PERSERIS™) is a once-monthly subcutaneous extended-release risperidone formulation approved for the treatment of schizophrenia in adults, designed to deliver clini...

Anne Andorn , MD;

James Graham , PharmD, BS Pharm, RPh;

Maurizio Fava , MD, PhD;

John Csernansky , MD;

John Newcomer , MD;

Anne Le Moigne , PhD;

10/08/2020

Characteristics of Commercially Insured Patients Initiated on Esketamine Nasal Spray in a Real-World Setting

BACKGROUND: Esketamine nasal spray was approved for adults with treatment-resistant depression on 03/05/2019. Real-world data on patients initiated on esketamine is limited. METHODS: Adu...

Laura Morrison , MPH;

Swapna Karkare , MS;

Abigail Nash , MD, PhD;

Maryia Zhdanava , MA;

Aditi Shah , MA;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

10/08/2020

Bipolar Disorder Treatment Patterns in the United States: A Retrospective Claims Database Study

Background: The objective of this retrospective study was to describe treatment patterns among patients with bipolar disorder.

Mehul Patel , MD, PharmD;

Patrick Gillard , PharmD, MS;

Amanda Harrington , PhD;

Amanda Kong , DrPH;

Rakesh Jain , MD, MPH, RD;

10/08/2020

Characteristics of young adults with schizophrenia using Colorado`s All Payer Claims Database (CO-APCD)

Background Schizophrenia (SCZ) is most likely to develop in young adulthood. Using data from a single state, we describe the demographic and clinical characteristics of young adults in t...

Charmi Patel , BS , RN, BSN, MPH;

Ravi Potluri ;

David Rotter ;

Jacqueline Pesa , PhD, MPH;

Eros Papademetriou , MA;

Carmella Benson , MSc, MS, MSHP;

10/08/2020

Budget Impact Analysis of Esketamine Nasal Spray in a Sub-Population of Adults With Major Depressive Disorder and High Unmet Need: Payer Perspective in the United States

Background: Esketamine nasal spray (ESK) plus comprehensive standard of care (SOC) vs placebo plus SOC was studied in two phase 3 antidepressant clinical trials among a sub-population of ...

Hoa Le , PhD;

Hector Toro-Diaz , PhD;

Shujun Li , MS;

John J. Sheehan , PhD, MBA, RPh;

Jennifer Voelker , MS, PharmD;

10/08/2020

Characterizing Management of Depression in a Primary Care Setting

Introduction: Depression is an important cause of disability in the US and is largely managed by primary care providers (PCPs). Understanding how PCPs manage depression is an important st...

Shruti Vaidya , MS;

Ivelina Popova , BSc;

Anqi Jin , PhD;

Sheetal Patel , MD;

Lambros Chrones , MD;

Alice Pressman , PhD, MS;

Maja Kuharic , PhD;

Maelys Touya , MSc, PharmD;

Debra Lawrence , PhD, MBA, MS;

Kristen Azar , RN, MSN, MPH, FAHA;

10/08/2020

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products